Edwards Lifesciences Corp  

(Public, NYSE:EW)   Watch this stock  
Find more results for ew
90.36
+0.11 (0.12%)
Real-time:   11:02AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 89.42 - 90.54
52 week 60.62 - 94.50
Open 90.20
Vol / Avg. 675,871.00/1.13M
Mkt cap 9.51B
P/E 12.89
Div/yield     -
EPS 7.01
Shares 105.30M
Beta 0.50
Inst. own 97%
Oct 27, 2014
Q3 2014 Edwards Lifesciences Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 29, 2014
Q2 2014 Edwards Lifesciences Corp Earnings Call - Webcast
Jul 29, 2014
Q2 2014 Edwards Lifesciences Earnings Release
Jun 12, 2014
Edwards Lifesciences at William Blair & Company LLC Growth Stock Conference
Jun 10, 2014
Edwards Lifesciences at Goldman Sachs Healthcare Conference
Jun 4, 2014
Edwards Lifesciences at Jefferies Global Healthcare Conference
May 8, 2014
Edwards Lifesciences Annual Shareholder Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 95.11% 19.15%
Operating margin 141.40% 25.19%
EBITD margin - 25.61%
Return on average assets 73.40% 15.84%
Return on average equity 134.78% 25.78%
Employees 8,600 -
CDP Score - -

Address

One Edwards Way
IRVINE, CA 92614
United States - Map
+1-949-2502500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular. In October 2012, it acquired BMEYE B.V.

Officers and directors

Michael A. Mussallem Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott B. Ullem Chief Financial Officer, Corporate Vice President
Age: 47
Bio & Compensation  - Reuters
Donald E. Bobo Jr. Corporate Vice President - Heart Valve Therapy
Age: 52
Bio & Compensation  - Reuters
Carlyn D. Solomon Corporate Vice President - Critical Care and Vascular
Age: 51
Bio & Compensation  - Reuters
Patrick B. Verguet Corporate Vice President, Europe, Middle East and Africa
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Huimin Wang M.D. Corporate Vice President, Japan, Asia Pacific
Age: 57
Bio & Compensation  - Reuters
Larry L. Wood Corporate Vice President - Transcatheter Valve Replacement
Age: 48
Bio & Compensation  - Reuters
Mike R. Bowlin Independent Director
Age: 71
Bio & Compensation  - Reuters
John T. Cardis Independent Director
Age: 72
Bio & Compensation  - Reuters
Robert A. Ingram Independent Director
Age: 71
Bio & Compensation  - Reuters